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The measurement and correlation of the experimental solubility of the antimalarial artemisinin (Artemisia annua
L.) in supercritical carbon dioxide is reported. Results were obtained using a static analytical method at 308.2,
318.2, and 328.2 K, and in a pressure range from 10.0 up to 25.0 MPa. Solubility experimental data were correlated
with three density-based models (Chrastil, Bartle, and Me´ndez-Santiago-Teja models) and with two cubic equation
of state (EOS) models, namely, the Peng-Robinson EOS and the Soave-Redlich-Kwong EOS, together with
the conventional van der Waals mixing and combining rules. Good correlation results were obtained between the
calculated and the experimental solubility to all fitted models. Results clearly show the feasibility of processing
this antimalarial drug using supercritical fluid technologies and processes.
Introduction
Solvents and processes in solution play a central role in the
majority of chemical and pharmaceutical industrial processes.
The pharmaceutical industry is one of the major industries
worldwide and wherein, for comprehensible reasons, safety and
ecological considerations on the use of volatile organic solvents
(VOCs) and other harmful solvents must be seriously taken into
account. The actual severe regulations on the use of these
solvents and on their residual level in the final products are a
major limitation to most of the traditional pharmaceutical
processes. Likewise, both the generation of polluted aqueous
waste streams and the energy used to remove water (or other
solvents) from final or intermediate products (i.e., drying steps)
make important contributions to global pollution. As such, it
seems obvious that there are economical, safety, and ecological
reasons and a real need to consider, innovate, and optimize either
organic solvent-free pharmaceutical processes or the use of
“green and environmental friendly” solvents. Supercritical fluids
(SCFs) have already proved to be an excellent alternative to
replace VOCs, harmful solvents, and other additives in many
types of chemical and pharmaceutical process operations.
Furthermore, SCFs also present unique properties that may
improve these processes as well as offer new and innovative
possibilities for the development of new products, with better
chemical, physical, morphological, and mechanical properties
and, consequently, leading to novel and improved final phar-
maceutical applications and products. In recent years, several
reviews of pharmaceutical processing (studied systems and
applied techniques) using SCFs have been published, demon-
strating the existing opportunities offered by these processes
and technologies.1-5
Carbon dioxide is the most used SCF due essentially to its
relatively low critical temperature and critical pressure (Tc )
304.3 K, Pc ) 73.7 bar), nontoxicity, noninflammability, and
low cost. Because of these favorable properties combined with
other typical properties of SCFs like their low viscosities, high
diffusivities, and liquid-like densities, supercritical carbon
dioxide (scCO2) has found many uses in the nutraceutical and
pharmaceutical fields, where its nontoxic nature displays a great
advantage. Moreover, its low critical temperature permits
supercritical processing at mild temperature conditions, avoiding
the possible degradation of thermally labile substances (like most
pharmaceuticals and nutraceuticals). Another important advan-
tage is that the elimination of residual solvent is complete, and
the recovery of final products is easier and cheaper when
compared with many traditional processes. Extraction and
separation of natural products,6-8 recrystallization and drug
particle formation,9-12 preparation of sustained drug delivery
systems,13-15 and as a solvent for pharmaceutical synthesis and
enzymatic catalysis16-18 are some examples of scCO2 potential
applications in the pharmaceutical, cosmetics, and nutraceutical
industries.
Artemisinin (Figure 1), also known by the chinese name
Quinghaosu, is an endoperoxide sesquiterpene lactone produced
by the aerial parts of Artemisia annua L. (Asteraceae, formerly
Compositae), which has been used as a potential and effective
antimalarial agent to vitiate the impact of multidrug resistant
strains of the malarial parasites, Plasmodium falciparum and
Plasmodium ViVax, including the human cerebral malaria.19-23
In addition, ethanolic extracts of A. annua L. also proved to be
antiulcerogenic and antitumoral, and its essential oils can be
used as repellents, bactericides, and antioxidants.8 Recently,
artemisinin and some of its derivatives also showed a strong
antifungal activity against the opportunistic pathogen Cryptoc-
cocus neoformans.24
Although the chemical synthesis of this drug and of its
derivatives (dihydroartemisinin, artemether, arteether, artesunic
acid, and artelinic acid) is already possible, the synthetic
products are not yet as competitive in price as the natural ones,
obtained by extraction and isolation from A. annua L.25-27 On
the other hand, apparently the pharmaceutical industry is not
interested in investing and producing antimalarial drugs because
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most of the infected people live in nondeveloped and developing
countries, where the pharmaceutical market is not attractive
enough, and there is insufficient patent protection.28 Therefore,
the most used method to obtain artemisinin is by liquid organic
solvent extraction from A. annua L. dried aerial parts (leaves,
stems, buds, and flowers). Typical employed solvents are
toluene, n-hexane, cyclohexane, ethanol, chloroform, and pe-
troleum ether.29-31 Microwave-assisted liquid solvent extraction
was also employed in order to increase liquid extraction
rates.31,32 However, and in general, the extracts obtained by
liquid solvent extraction contain large amounts of undesired
compounds such as chlorophyll and other organic molecules.
This will decrease the extraction selectivity and will introduce
difficulties in the drug purification process, leading to low
extraction yields.8 Moreover, its peroxide bridge, which is
essential for its activity, is very reactive and may react with
compounds used in the purification of extracts. Finally, liquid
solvent extractions frequently require dehydrated or dried plant
material, and it is well-established that the employed drying
methods can have a strong influence on the final artemisinin
recovery.31 Recently, scCO2 extraction proved to be a promising
alternative to extract artemisinin from the dried plant mater-
ial.8,33,34 Supercritical technology was also used to produce
artemisinin particles by rapid expansion of supercritical solutions
(RESS), which showed improved dissolution properties.9
However, for the design of any pharmaceutical process based
in SCF technology (SCF extraction, drug particle formation SCF
techniques, etc.), the accurate knowledge of the equilibrium
solubility data, in different conditions of temperature and
pressure, between the pharmaceutical compounds of interest and
the SCF solvent is required. Performing a quick search through
the literature, one can easily find data on the solubility (in
scCO2) of several drugs and other biomolecules of pharmaceuti-
cal interest, determined using different experimental meth-
ods.2-5,10-12,35-42 Modeling and correlation of the solubility of
solids in scCO2 were also extensively investigated.43-51
Solid solubilities in SCFs (and drug solubilities in particular)
are not easy to predict because there is a lack of accurate models
to simulate and predict equilibrium solubilities of these com-
pounds in SCFs and there is not much information regarding
most physical properties necessary for those available models.
Furthermore, when applying these predictive models, other
complications may come up like, for example, their failure
because these mixtures are usually very asymmetric in terms
of size and energy differences between the components: for
example, solid solute molecules are usually large and polar (like
most drugs) while supercritical solvent molecules are usually
small and show low polarity (like CO2).51
If not completely predicted or determined experimentally,
drug solubility in SCFs must be obtained and extended through
correlations based on theoretical or empirical models applied
to the existing experimental data. Generally, the most common
models used for correlating solid-supercritical phase equilibria
are cubic equations of state (EOSs), noncubic EOSs, activity
coefficient models, and semiempirical correlations based on
density, pressure, and temperature.52 Undoubtedly, the most used
models are cubic EOSs from the van der Waals family, like the
Peng-Robinson53 (PR) and Soave-Redlich-Kwong54 (SRK)
EOSs, together with several mixing and combining rules, like
the classical van der Waals mixing rules (vdW). The above
referred EOS models require one or more temperature-dependent
interaction parameters that must be correlated from the experi-
mental solubility data. In addition, EOS models need data on
several critical and other physicochemical properties of solutes
that are not always available in the literature, mainly for
pharmaceutical compounds and other less common substances.
In general, these solid’s properties (critical properties, molar
volume, sublimation pressure, and Pitzer’s acentric factor) are
not yet experimentally determined and have to be predicted by
several estimation and group-contribution methods (sometimes
not very reliable). Consequently, this may introduce additional
errors on the correlation results or may originate very unlike
adjusted parameters results, depending on the applied methods.
Therefore, extreme caution should be taken when choosing and
applying these estimation methods. To avoid some of these
difficulties as well as more complicated computational routines,
most authors decide to use several empirical correlations such
as density-based correlations43-45 (Chrastil, Bartle, and Me´ndez-
Santiago-Teja models) or the Ziger-Eckert semiempirical
correlation.50 These models are based on simple error minimiza-
tion using least-squares methods, and for the majority of them,
there is no need to estimate and use critical and thermophysical
properties of the involved solids.
Despite the above referred disadvantages and difficulties
associated to these correlation models, they are widely employed
and normally used to fit and correlate solubility experimental
data for a given envisaged practical purpose. Thus, they are
very helpful for the development of supercritical applications
and processes that require the accurate knowledge of solid
solubility in SCFs. However, and like most correlation models,
even for other applications, they should be preferably employed
just in the experimental data range (i.e., for interpolation of
results). Using these models to extrapolate to outside the
experimental data range should be performed very carefully (it
can be done, but for regions very near to the limits of the
experimental data range). Extrapolation for other regions, far
from this range, can originate unreliable results.
Only recently the solubility of artemisinin in scCO2 was
measured, at four isotherms, correlated and reported,55 using a
flow-type apparatus equipped with a high-pressure UV detector.
Correlation on the experimental data was done using a density-
and temperature-based equation. In the present work, the
equilibrium solubility of artemisinin in scCO2 was measured,
from 10.0 up to 25.0 MPa, and at 308.2, 318.2, and 328.2 K,
using a static analytical method. Results were compared to the
ones obtained by Ren and co-workers.55 Experimental data were
correlated using three different density-based correlations
(Chrastil, Bartle, and Me´ndez-Santiago-Teja models) and by
the PR and SRK EOSs, together with the conventional van der
Waals mixing and combined rules.
Experimental Section
Materials. Carbon dioxide (CAS 124-38-9) (purity > 99.998
%) was purchased from Praxair, dichloromethane (CAS 75-09-
2) (purity > 99.9 %) was obtained from Fluka. Artemisinin
Figure 1. Chemical structure of artemisinin (Artemisia annua L.).
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(CAS 63968-64-9) (from Mediplantex, analytical grade) was
kindly supplied by Prof. Mitchel A. Avery from the University
of Mississipi.
Experimental Procedure. The experimental solubility of
artemisinin in scCO2 was measured using a static equilibrium
method and following a experimental procedures already
described in detail.5,36,52 A stainless steel equilibrium visual cell,
with an internal volume of approximately 30.0 cm3, was loaded
with the solid solute and a magnetic stirrer and immersed in a
thermostatic water bath. A ThermoHaake temperature controller
maintained the operational temperature within ( 0.1 K. The
system was pressurized with CO2 by means of a high-pressure
liquid pump, and the pressure inside the cell was measured with
a high-pressure transducer (Setra, model 204, 0.0-34.40 ( 0.04
MPa), calibrated between 0 and 20.5 MPa. When the desired
operational temperature and pressure were attained, the solid
+ CO2 mixture was stirred during 1 h, for equilibration and
fluid phase saturation. We carried out several preliminary
experiments in order to determine the amount of solubilized
drug as a function of equilibration and saturation time. For this
compound, the required saturation time was around 30 min.
Nevertheless, we kept the saturation process for 60 min (with
strong stirring) plus a 20 min period without stirring. A sample
was then taken, using a six-port sampling valve (Rheodyne high-
pressure switching valve, model 7060) and a sampling loop of
approximately 0.5 cm3. The sample was quickly depressurized
and the precipitated solid was collected in a small glass trap.
The gas in the sample was expanded into a large precalibrated
volume, composed by a glass trap (15.9 cm3) and a metal
balloon (1735.05 cm3), and previously brought into sub-
atmospheric pressure. The amount of CO2 in the sample was
calculated based on the resulting sub-atmospheric pressure
increase, which was measured with a high precision low-
pressure transducer (Setra, model 204, 0.0-0.175 ( 1.9  10-4
MPa). To ensure that all solute was recovered, a cleaning solvent
(dichloromethane) was injected through the sample loop and
the expansion lines and recollected in the glass trap. Lines were
also cleaned with fresh CO2, smoothly pressurized.
Analytical Method. The amount of solubilized solid drug was
determined by spectrophotometric UV analysis. The collected
samples, containing the solid drug, were diluted in dichlo-
romethane to a convenient volume, and the absorbancies of the
resulting sample solutions were measured, at fixed wavelength
(229 nm), by a UV/VIS spectrophotometer (JASCO V-530).
Calibration curve was obtained by UV analysis of previously
prepared standard samples, with concentrations between 0.5 and
3 mg/mL.
For each sample, the amount of CO2 was calculated using
the Virial EOS (applied to pure CO2), the values of the
precalibrated expansion volumes, the resulting sub-atmospheric
pressure increase due to expansions, the temperature of the water
bath (( 0.01 K), and the temperature of the glass trap (which
was considered to be 273.15 K).
Correlation of Experimental Solubility Data
Density-Based Models. The Chrastil model43 relates the
solubility of a solid solute in a SCF as a function of the density
of the pure SCF and of the absolute temperature. It is based on
the supposition that one molecule of solute, A, associates with
k molecules of solvent, B, to form a solvate complex, ABk, in
equilibrium with the system. Taking in consideration several
thermodynamic considerations, it is easy to obtain the following
expression for the solid solubility in a SCF:
In this expression, S (kgâm-3) is the solubility of the solid in
the supercritical phase; F (kgâm-3) is the density of the pure
supercritical fluid; k is the association number; R is a constant,
defined as ¢H/R (where ¢H is the sum of the enthalpies of
vaporization and solvation of the solute and R the gas constant);
and â is another constant related to the molecular weight of the
solute and solvent. The parameters k, R, and â are obtained
performing a multiple linear regression on the obtained experi-
mental solubility data.
Bartle et al.44 proposed another simple density-based semiem-
pirical model to correlate the solubility of solids in SCFs:
In these expressions, pref is assumed as a standard pressure of
0.1 MPa (1.0 bar); Fref is a reference density, assumed as 700
kgâm-3; and a1, a2, A, and C are empirical constants, determined
in the following way: from the experimental solubility data,
each isotherm is fitted using eq 2, to obtain the values of A and
C. In this model, the parameter a2 is related to the enthalpy of
sublimation of the solid solute, ¢Hsub, by the expression ¢Hsub)
-Ra2 (R is the gas constant).
Finally, and based on the theory of dilute solutions, Me´ndez-
Santiago and Teja45 proposed a simple linear expression to
correlate the solubility of solids in SCFs:
where A′, B′, and C′ are constants, considered as temperature
independent, and obtained by a multiple linear regression of
solubility experimental data.
EOS-Based Models. The solubility of a solid solute (2) at
equilibrium with a fluid at high pressures (1) can be calculated
using the following well-known expression:
In this expression, p2
sub is the sublimation pressure of the pure
solid at temperature T, V2 is the molar volume of the solid, and
æ2
SCF is the fugacity coefficient of the solid in the fluid phase,
which expresses the nonideality of the fluid phase. This fugacity
coefficient is usually evaluated using an EOS. In this work, the
Peng-Robinson53 EOS (eq 7) and the Soave-Redlich-
Kwong54 EOS (eq 8) were used:
To use the above EOSs, for a binary solid + SCF mixture, we
employed the classical van der Waals (vdW) mixing and
ln S ) k ln F + R/T + â (1)
ln( yppref) ) A + C(F - Fref) (2)
A ) a1 + a2/T (3)
ln( yppref) ) a1 + a2/T + C(F - Fref) (4)
T ln(yp) ) A′ + B′F + C′T (5)
y2 )
p2
sub
p
1
æ2
SCF exp[V2(p - p2sub)RT ] (6)
p ) RT
V - b -
a
V(V + b) + b(V - b) (7)
p ) RT
V - b -
a
V(V + b) (8)
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combining rules, with one or with two adjustable parameters,
kij and lij:
The binary interaction parameters, kij and lij, are obtained by
fitting experimental data, through the minimization of an
objective function, the average absolute relative deviation
(AARD), defined as
In this equation, N is the number of experimental data points,
ycal is the calculated solubilities, and yexp is the experimental
solubility data points.
Results and Discussion
The solubility of artemisinin in scCO2 was determined at
308.2, 318.2, and 328.2 K, in the pressure range from 10.0 up
to 25.0 MPa, following the method described in the Experi-
mental Section. Results are summarized in Table 1. For each
isotherm, experimental data points (at a certain pressure) are
an average of, at least, three experimental solubility measure-
ments. Each (p, T, y) data point is accepted if the corresponding
standard deviation is less than ( 5 %. The overall uncertainty,
taking in consideration the random uncertainties (statistical,
associated to Beer-Lambert’s calibration curve and to the
average of the experimental solubility measurements) and the
systematic uncertainties (uncertainties due to the preparation
of standard calibration solutions and to pressure and temperature
measurements) was found to less than 1.2  10-4 (in y, mole
fraction of artemisinin).
At the studied conditions, the solubility of artemisinin in
scCO2, in terms of mole fraction, ranges from 10-4 to 10-3,
which is higher than the typical solubilities of many drugs and
molecules of biological and pharmaceutical interest. Generally,
these compounds have a relatively low solubility, usually around
or inferior to 10-4, in terms of mole fraction, at the same
investigated pressure range and temperatures.2-5,10-12,35-42
It is well-known that the solubility of a solid in a SCF depends
essentially on the specific interactions between the solid solute
and the SCF as well as on the molecular weight of the solid
(and on pressure and temperature). If the SCF is a small nonpolar
molecule (like CO2), one should anticipate that strong polar high
molecular weight substances (like most drugs) are hard to
dissolve (or even insoluble) in scCO2. From Figure 1, we can
see that artemisinin is a large molecule (Mw ) 282.33 gmol-1),
and from its structure, we may expect that it is a strong polar
molecule. Polarity can be discussed in terms of the dipole
moments of substances. But, dipole moments are not easy to
calculate/estimate, and usually it is difficult to find any available
and/or consistent values in the literature for this kind of
substances. Even when using molecular simulation programs
to estimate these values, it is a very difficult task because most
drugs possess stereoisomers and each stereoisomer can present
several conformers, having different dipole moments.
Artemisinin’s dipole moment was found to be around 6.14
D, calculated by a molecular mechanics (MM2) force field
model and by a semiempirical molecular orbital model (MO-
PAC).56 Therefore, we should expect a low solubility in scCO2
and not a relatively high solubility like the one experimentally
observed. Thus, these high solubility values may be due to some
specific interactions that may occur between artemisinin and
scCO2 like, for example, specific interactions that may take place
between its carbonyl group and scCO2.57-59 Another possible
explanation could be the interactions that may happen between
the lone pairs of electrons at oxygen atoms of artemisinin
(peroxide, ether, and lactone groups) and scCO2. It is known
that CO2 has a large quadrupole moment60 as a result of its
highly electronegative oxygen atoms, and it is credible that it
may lead to a favorable quadrupole-dipole interaction between
CO2 and artemisinin.
In Figure 2, we compare our experimental data, at 318.2 K
and 328.2 K, with the experimental solubility data previously
reported by Ren and co-workers55 at 318.1 K and 328.1 K,
measured with a flow-type apparatus, equipped with a high-
pressure UV detector. As can be seen, and despite the different
employed experimental methods, our results are in quite good
Figure 2. Comparison between this work (filled symbols) and the work reported by Ren et al.55 (open symbols) at 318.2 K (triangles) and 328.2 K (squares).
Table 1. Experimental Solubility (y) of Artemisinin in Supercritical
Carbon Dioxide
T ) 308.2 K T ) 318.2 K T ) 328.2 K
p/MPa F/kgâm-3 y  103 p/MPa F/kgâm-3 y  103 p/MPa F/kgâm-3 y  103
10.4 720.7 0.701 10.4 539.2 0.603 13.5 586.9 0.847
13.2 786.5 0.925 15.3 743.9 1.191 15.9 672.2 1.284
16.3 828.5 1.134 18.0 786.5 1.610 18.5 727.4 1.908
18.6 851.0 1.521 21.3 823.3 1.825 22.1 777.8 2.237
21.6 876.3 1.716 24.3 849.3 2.009 24.7 804.7 2.514
25.2 900.4 1.788
a ) ∑
i
∑
j
yiyj(aiaj)0.5(1 - kij) (9)
b ) ∑
i
∑
j
yiyj(bi + bj2 )(1 - lij) (10)
AARD/% )
100
N ∑n
jycal - yexpj
yexp
(11)
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agreement with the already published data (except for the lower
pressure points, where the discrepancy is generally higher).
In the above cited work, Ren and co-workers fitted their
experimental solubility data (for four isotherms (310.1 K, 318.1
K, 328.1 K, and 338.1 K) using the correlation:
They obtained the following fitted parameters (for AARD
referred as 4.24 %): a ) 2.162; b ) 0.002238; c ) -2795.485;
and d ) -26.311. In Table 2, we present the calculated
artemisinin’s solubility using Ren’s correlation and fitted
parameters (for each temperature and pressure data point), and
we compared these results with our experimental values. As
referred at the graphical analysis (Figure 2), results are, in
general, in good agreement except for lower values of pressure.
These differences may be due to the diverse employed experi-
mental methods. A possible cause to these different values may
be due the different fluid phase saturation periods used at each
method. Ren’s method, at lower pressures, just allowed an initial
total saturation period of less than 20 min and then pressure
was increased in sequential steps, while we used around 80 min
of saturation time for every point. Therefore, at 318.2 K and
328.2 K and because of lower fluid phase densities, incomplete
saturation can be achieved at these lower pressures, originating
lower solubility values than the ones obtained in our work. At
308.2 K, Ren and co-workers did not report the experimental
solubility results, but we also determined these values using
their correlation. For this isotherm, Ren’s correlation originated
higher solubility values than the ones obtained in our work (for
lower pressures). However, we cannot be sure if their correlation
can be confidently used outside the experimental temperature
range for which the correlation parameters were determined.
The three density-based (Chrastil, Bartle, and Me´ndez-
Santiago-Teja models) correlation results are presented in Table
3 and represented in Figures 3 to 5. To all the employed models,
the quality of the correlation is expressed in terms of the AARD.
All the three density-based models were able to successfully
correlate the experimental artemisinin + scCO2 solubility data,
with AARD values around 8 to 12 %.
As referred in Introduction, cubic EOS models need data on
several critical and other physicochemical properties of solutes
that are not always available in the literature, namely, critical
properties, molar volume, sublimation pressure, and Pitzer’s
acentric factor. Therefore, these properties have to be predicted
by several estimation and group-contribution methods, which
Table 2. Comparison between the Solubility Data
T ) 308.2 K T ) 318.2 K T ) 328.2 K
p/MPa
y 
103 a
y 
103 b
dev/
%
p/
MPa
y 
103 a
y 
103 b
dev/
%
p/
MPa
y 
103 a
y 
103 b
dev/
%
10.4 0.783 0.701 10.5 10.4 0.397 0.603 51.9 13.5 0.741 0.847 14.2
13.2 1.096 0.925 15.6 15.3 1.259 1.191 5.4 15.9 1.203 1.284 6.7
16.3 1.348 1.134 15.9 18.0 1.562 1.610 3.1 18.5 1.615 1.908 18.2
18.6 1.502 1.521 1.3 21.3 1.872 1.825 2.5 22.1 2.090 2.237 7.1
21.6 1.693 1.716 1.4 24.3 2.122 2.009 5.3 24.7 2.388 2.514 5.3
25.2 1.895 1.788 5.6
a Obtained by the correlation of Ren and co-workers.55 b Obtained
experimentally, this work.
Table 3. Correlated Parameters and Correspondent AARD Values,
Obtained from Experimental Data Correlation Using Chrastil,
Bartle, and Me´ndez-Santiago-Teja Models
Chrastil Model, eq 1
k 4.1
R/K -3846.1
â -13.35
¢H/(kJâmol-1) -32.0
AARD/% 8.4
Bartle Model, eq 4
a1 19.18
a2/K -6720.6
C/(m3âkg-1) 0.008
¢Hsub/(kJâmol-1) 55.9
AARD/% 11.6
Me´ndez-Santiago-Teja Model, eq 5
A′/K -8154.5
B′/(Kâm3âkg-1) 2.4
C′ 26.1
AARD/% 11.8
ln(y) ) a ln(FT) + bF + c/T + d (12)
Figure 3. Logarithmic relationship between the solubility of artemisinin
in scCO2 and the density of pure CO2. Experimental: 2, 308.2 K; ], 318.2
K; 9, 328.2 K; s, calculated by eq 1, Chrastil’s model.
Figure 4. Solubility of artemisinin in scCO2 as a function of the density
of pure CO2. Experimental: 2, 308.2 K; ], 318.2 K; 9, 328.2 K; s,
calculated by eq 4, Bartle’s model.
Figure 5. Relationship between the solubility of artemisinin and the density
of pure CO2. Experimental: 2, 308.2 K; ], 318.2 K; 9, 328.2 K; s,
calculated by eq 5, Me´ndez-Santiago-Teja’s model.
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sometimes are not very trustworthy. Consequently, this may
introduce additional errors on the EOS correlation results or
may originate very unlike adjusted parameters results, depending
on the applied methods. Therefore, some prudence should be
taken when selecting and applying these estimation methods.
In some previous work,51,52 we already discussed the influence
of these group-contribution methods on the estimation of these
required properties and their consequences on the final EOS
correlation results. Accordingly, for artemisinin, these properties
were estimated using the group-contribution methods indicated
in Table 4.51,61,62
In Table 5, we present the optimal fitted binary parameters
and the respective AARD values, obtained by experimental data
correlation using the PR-EOS and the SRK-EOS, combined with
the van der Waals mixing and combining rules, with one
adjustable parameter (vdW1) and with two adjustable parameters
(vdW2).
Correlation results obtained with the PR-EOS and SRK-EOS,
in respect to AARD values, are very similar, both for vdW1
and vdW2 mixing and combining rules. As expected, the best
correlations, for both EOSs, were obtained for the vdW2 mixing
and combining rule, with two adjustable parameters. Of course,
this can be explained by the fact that a model with two
adjustable parameters has more “flexibility” to fit the experi-
mental data than a model with only one adjustable parameter,
such as vdW1. Figure 6 shows the correlation of experimental
solubility data obtained with the PR-EOS, using vdW2 mixing
and combining rule. Correlated curves evidence the retrograde
solubility behavior characteristic of most of the solid/SCF
systems, which is caused by the opposite effect of temperature
on the density of the supercritical fluid and on the sublimation
pressure of the solid solute. For this system, this so-called
“crossover region”, where one can observe the intersection of
the solubility isotherms, is located between 13.0 MPa and 17.0
MPa.
One of our objectives in determining the experimental
solubility of artemisinin in scCO2 carbon dioxide is to make
use of the obtained data (experimental and correlated) for the
design and development of supercritical processes based on this
drug (like particle formation and supercritical solvent impregna-
tion techniques). And, for these purposes, the accurate knowl-
edge of drug solubility and the quality and confidence of the
applied correlations is indispensable (for interpolations inside
the experimental ranges investigated). To improve the confi-
dence on our correlated results, we must also try to perceive
the effect of the overall uncertainty of the experimental data on
the correlation results. A feasible way to do this is to consider
the obtained overall uncertainty associated with all experimental
data points and then, “create” two new sets of “experimental”
data points: one consisting of their average experimental value
added by the overall uncertainty and the other consisting of their
average values subtracted by the same overall uncertainty.
Subsequently, we must correlate the models, using these two
new “experimental” sets of data points. Applying this procedure,
we will obtain an “area” in which drug solubility, with some
degree of confidence, should be comprised.
As an illustrative example of this procedure, we applied the
PR-EOS, together with the vdW2 mixing and combining rule
(vdW2, with two adjustable parameters), for the experimental
results obtained at 308.2 K. Results are summarized in Table 6
and presented in Figure 7.
As can be seen, we will get an area of “probable” drug
solubility, as a function of pressure, for each isotherm, which
is located between the curves obtained for the correlation of (y
+ OU) and (y - OU) data. Interaction parameters showed a
relative error (to the experimental average solubility correlated
parameters) of 6.8 to 10.4 % (for k12) and 25.2 to 31.3 % (for
l12). AARD values are similar for the three performed correla-
tions.
Therefore, this procedure may provide more confidence for
the selection of the operational (p, T) conditions to apply in the
development of any supercritical process that requires the
solubility data of this drug in scCO2. However, as as already
referred, this should be employed just in the experimental data
range (i.e., for interpolation of results). Similar procedures can
be done for other EOS models as well as for the presented
density-based models (Chrastil, Bartle, and Me´ndez-Santiago-
Teja models).
Table 4. Estimated Critical and Other Required Thermophysical
Properties of Artemisinin
Tb Tc pc 106  V2 p2sub  103/MPa
K K MPa ö m3âmol-1 308.2 K 318.2 K 328.2 K
560.1a 767.7a 2.445a 0.603b 211.5c 0.671b 1.719b 4.110b
a Estimated by Constantinou-Gani (first-order) method.61 b Estimated
by the Ambrose-Walton corresponding states method.61 c Estimated by
Fedors’ method.62
Table 5. Correlation Results for the Solubility of Artemisinin in
scCO2, Obtained with the Peng-Robinson and the
Soave-Redlich-Kwong Equations of State
PR-EOS SRK-EOS
T/K
mixing
rule k12 l12 AARD/% k12 l12 AARD/%
308.2 vdW1 0.188 19.0 0.200 21.7
vdW2 0.250 0.144 6.2 0.270 0.169 6.6
318.2 vdW1 0.184 9.0 0.193 10.8
vdW2 0.219 0.075 8.4 0.243 0.105 9.1
328.2 vdW1 0.186 9.6 0.196 11.5
vdW2 0.233 0.100 2.5 0.250 0.120 2.7
Figure 6. Solubility of artemisinin in scCO2. Experimental: 2, 308.2 K;
], 318.2 K; 9, 328.2 K; s, calculated with the PR-EOS and the vdW2
mixing and combining rule (two adjustable parameters).
Table 6. Correlation Results for the Solubility of Artemisinin in
scCO2, Obtained with the PR-EOS, and the vdW2 Mixing and
Combining Rule
T PR-EOS-vdW2
K k12 l12 AARD/%
y - OUc 0,276 0,189 6,26
308.2 ya 0,250 0,144 6,20
y + OUb 0,233 0,115 6,15
a Applied to the average experimental solubility (y). b Applies to the
average experimental solubility, added by the overall uncertainty (y + OU).
c Applied to the average experimental solubility, subtracted by the overall
uncertainty (y - OU).
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Conclusions
The solubility of artemisinin in scCO2 was measured and
correlated at various pressures and temperatures (at 308.2 K,
318.2 K, and 328.2 K, in the pressure range from 10.0 MPa up
to 25.0 MPa). Experimental results were compared with those
in the existing literature, and good agreement was found despite
different experimental methods are different. Results clearly
show the feasibility of processing this antimalarial drug using
supercritical fluid technologies and processes. Furthermore, these
results may be an indication that, possibly, other artemisinin’s
derivatives will be also soluble in scCO2.
The obtained high solubility values were discussed in terms
of possible and potential specific interactions that may occur
between artemisinin and scCO2 like, for example, those that
may take place between its carbonyl group and scCO2 as well
as other interactions which may occur between the lone pairs
of electrons at oxygen atoms of artemisinin (peroxide, ether,
and lactone groups) and scCO2 (quadrupole-dipole interaction
between CO2 and artemisinin).
Results were correlated with several models found in the
literature: three density-based models (Chrastil, Bartle, and
Me´ndez-Santiago-Teja models), and with two cubic EOS
models, namely, the PR-EOS and the SRK-EOS, together with
the conventional van der Waals mixing and combining rules.
All fitted models were shown to be able to successfully correlate
experimental solubility data.
The correlation models used in this work proved to be very
helpful for the development of supercritical applications and
processes that require the precise knowledge of artemisinin’s
solubility in scCO2. A simple procedure, introducing the effect
of the experimental overall uncertainty, was suggested in order
to provide more assurance for the selection of the operational
(p, T) conditions to apply in the development of these super-
critical processes. However and like most correlation models,
they should be employed just in the experimental data range
(i.e., for interpolation of results). Extrapolation for other regions,
far from this range, can originate unreliable results.
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